Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.

PHASE4CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

November 8, 2017

Primary Completion Date

February 10, 2020

Study Completion Date

February 10, 2020

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Selexipag

Film-coated tablets for oral use; one tablet (200 mcg) to eight tablets (1600 mcg) are administered depending on the individual tolerability.

DRUG

Placebo

Matching film coated tablets

Trial Locations (39)

4020

Krankenhaus der Elisabethinen, Servicestelle Klinische Studien, Linz

8091

Universitaetsspital Zurich, Klinik für Pneumologie C HOER 11, Zurich

9007

Kantonsspital St. Gallen, Klinik für Pneumologie und Schlafmedizin, Sankt Gallen

11501

NYU Winthrop Hospital, Mineola

19104

University of Pennsylvania, Pulmonary Vascular Disease Program, Philadelphia

27599

UNC Pulmonary Speciality Clinic, Chapel Hill

27710

Duke University School of Medicine, Duke Pulmonary Vascular Disease center, Durham

30342

Northside Hospital, Atlanta

31059

Hospital Larrey CHU de Toulouse, Toulouse

35392

Universitätsklinikum Giessen, Giessen

40202

Kentuckiana Pulmonary Research Center, Louisville

44307

CCF- Akron General Medical Hospital, Cleveland

44534

Katholisches Klinikum Lünen/Werne GmbH, Haus E, Lünen

50937

Herzzentrum der Universität zu Köln, Klinik III für Innere Medizin, Cologne

59000

CHRU de Lille - Hôpital Albert Calmette, Service de cardiologie, Lille

68198

University of Nebraska Medical Center, Pulmonary, Critical Care & Sleep Medicine Division, Omaha

73112

Integris Baptist Medical Center, Oklahoma City

78229

Methodist Clinical Trials, San Antonio

University of Texas Health Science Center (San Antonio), San Antonio

90502

LA Biomedical Research Institute, Torrance

94270

Hôpital Bicêtre, ervice de Pneumologie et Réanimation respiratoire, Le Kremlin-Bicêtre

02111

Tufts Medical Center, Pulmonary/Critical Care & Sleep, Boston

45267-0564

University of Cincinnati, Heart, Lung and Vascular Institute, Cincinnati

37232-2650

Vanderbilt University Medical Center, Care Medicine, Nashville

06020

Medizinische Universität Innsbruck (MUI), Abt. für Pneumologie, Haus 2, Innsbruck

04103

Universitätsklinikum Leipzig AöR, Abteilung Pneumologie, Leipzig

D07 R2WY

Mater Misericordiae University Hospital, Dublin

0372

Oslo University Hospital, dept of cardiology, Oslo

3000-075

Centro Hospitalar e Universitário de Coimbra, Serviço de Cardiologia, Coimbra

4099-001

Hospital Geral de Santo António-DEFI, Porto

413 45

Sahlgrenska University Hospital, Gothenburg, Gothenburg

221 85

Skåne University Hospital, VO Hjärt och Lungmedicin, Lund

Cb23 3RE

Papworth Hospital, Pulmonary Vascular Disease Unit, Cambridge

G81 4DY

Golden Jubilee National Hospital, Scottish Pulmonary Vascular Unit, Clydebank

NW3 2QG

The Royal Free Hospital, Cardiology Department, London

SW3 6NP

Royal Brompton Hospital, Hypertension, London

W12 0HS

Hammersmith Hospital, London

NE7 7DN

Freeman Hospital, Cardiothoracic Department, Newcastle upon Tyne

S10 2JF

Royal Hallamshire Hospital, Pulmonary Vascular Medicine, Sheffield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Actelion

INDUSTRY

NCT03078907 - Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension. | Biotech Hunter | Biotech Hunter